The irreversible FGFR inhibitor futibatinib is currently under evaluation in a phase III clinical study in patients with advanced cholangiocarcinoma harboring FGFR2 gene rearrangements (ClinicalTrials.gov Identifier: NCT04093362). Here, FGFR2 is linked to cholangiocarcinoma.